Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$115.81M-462%-$20.6M-31.9%-$15.62M-49.9%-$10.42M-138%$27.61M+143%
$22.9K-71.0%$78.9K-36.8%$124.9K-24.8%$166K-17.1%$200.3K+3.6%
$10.39M+5.2%$9.87M+5.7%$9.34M+1.8%$9.18M+2.8%$8.93M-17.6%
-$107.78M-10.6%-$97.43M-2.3%-$95.25M+0.3%-$95.56M-84.6%-$51.76M+13.1%
$926K-36.8%$1.47M-11.4%
$95.34M+73,239%
$173.73M+608%
-$107.78M-10.0%-$97.99M-2.1%-$95.99M+0.5%-$96.49M-81.3%-$53.23M+13.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Whitehawk Therapeutics, Inc. Common Stock generate?
Whitehawk Therapeutics, Inc. Common Stock (WHWK) generated -$107.8M in operating cash flow over the trailing twelve months.
What is Whitehawk Therapeutics, Inc. Common Stock's free cash flow?
After $738.0K of capital expenditures, Whitehawk Therapeutics, Inc. Common Stock's free cash flow was -$107.8M over the trailing twelve months, down 102.5% year over year.
Where does Whitehawk Therapeutics, Inc. Common Stock's cash flow data come from?
Every line is extracted from Whitehawk Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.